Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.91 -7.9%	$1.08	$0.91 ▼ $2.20	$29.79M	0.92	55,125 shs	118,921 shs
NRXP NRx Pharmaceuticals	$3.26 +0.9%	$2.53	$1.10 ▼ $6.01	$55.84M	1.54	414,513 shs	198,244 shs
PHIO Phio Pharmaceuticals	$2.27 -3.8%	$2.14	$0.97 ▼ $9.79	$11.32M	0.84	2.44 million shs	171,606 shs
PRLD Prelude Therapeutics	$0.86 -0.1%	$0.90	$0.61 ▼ $6.80	$48.62M	1.25	281,968 shs	108,690 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	-7.88%	-2.98%	-11.46%	-35.32%	-48.18%
NRXP NRx Pharmaceuticals	+0.93%	-5.23%	+23.95%	+56.73%	+6.89%
PHIO Phio Pharmaceuticals	-3.81%	0.00%	+26.82%	+75.97%	-64.62%
PRLD Prelude Therapeutics	-0.07%	-10.37%	-5.86%	+21.09%	-77.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYAI Dyadic International	1.7557 of 5 stars	3.5	2.0	0.0	1.7	0.0
NRXP NRx Pharmaceuticals	2.1202 of 5 stars	3.6	1.0	3.0	0.8	0.6
PHIO Phio Pharmaceuticals	3.0813 of 5 stars	3.5	5.0	1.1	2.5	0.6
PRLD Prelude Therapeutics	3.2153 of 5 stars	3.5	2.0	0.0	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	3.00	Buy	$6.00	557.89% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	774.23% Upside
PHIO Phio Pharmaceuticals	3.00	Buy	$14.00	516.74% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	422.95% Upside

Current Analyst Ratings Breakdown

Latest PHIO, PRLD, DYAI, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/5/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00
4/8/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/8/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.49M	7.86	N/A	N/A	$0.08 per share	11.40
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$0.69 per share	N/A
PRLD Prelude Therapeutics	$7M	6.94	N/A	N/A	$2.39 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$5.81M	-$0.20	N/A	N/A	N/A	-163.94%	-233.69%	-59.37%	8/12/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
PHIO Phio Pharmaceuticals	-$7.15M	-$10.92	N/A	0.60	N/A	N/A	-105.65%	-89.19%	8/13/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)

Latest PHIO, PRLD, DYAI, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/14/2025	Q1 2025	DYAI Dyadic International	N/A	-$0.07	N/A	-$0.07	N/A	$0.39 million
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A
3/26/2025	Q4 2024	DYAI Dyadic International	-$0.04	-$0.05	-$0.01	-$0.05	$1.60 million	$0.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	5.40	3.98	3.98
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
PHIO Phio Pharmaceuticals	N/A	10.58	10.58
PRLD Prelude Therapeutics	N/A	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
NRXP NRx Pharmaceuticals	4.27%
PHIO Phio Pharmaceuticals	57.31%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	29.50%
NRXP NRx Pharmaceuticals	19.00%
PHIO Phio Pharmaceuticals	0.59%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	7	30.09 million	21.21 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
PHIO Phio Pharmaceuticals	10	4.80 million	4.77 million	Not Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable

PHIO, PRLD, DYAI, and NRXP Headlines

Recent News About These Companies

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC

June 8, 2025 | marketbeat.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.com

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 5, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in Stock

March 28, 2025 | insidertrades.com

Prelude Therapeutics stock surges on insider buying

March 27, 2025 | investing.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

March 15, 2025 | insidertrades.com

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements

March 14, 2025 | msn.com

Analysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)

March 12, 2025 | markets.businessinsider.com

Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)

March 12, 2025 | markets.businessinsider.com

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

March 10, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, PRLD, DYAI, and NRXP Company Descriptions

Dyadic International NASDAQ:DYAI

$0.91 -0.08 (-7.88%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.94 +0.03 (+3.40%)

As of 06/20/2025 07:58 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

NRx Pharmaceuticals NASDAQ:NRXP

$3.26 +0.03 (+0.93%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.25 -0.01 (-0.31%)

As of 06/20/2025 07:59 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Phio Pharmaceuticals NASDAQ:PHIO

$2.27 -0.09 (-3.81%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.23 -0.04 (-1.76%)

As of 06/20/2025 06:50 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$0.86 0.00 (-0.07%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.88 +0.02 (+2.85%)

As of 06/20/2025 06:59 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time